GRAIL, Inc. (GRAL) stock
GRALNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$115.89−5.46 (-4.50%)
Close on Nov 13, 2026Market cap $5.18BP/E –Yield –
Grail EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Grail's EPS for the twelve months ending Sep 30, 2026 was -$9.49. For fiscal 2025 it was -$11.11.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.11 | – |
| FY2024 | Dec 31, 2024 | -$63.54 | – |
| FY2023 | Dec 31, 2023 | -$47.21 | – |
| FY2022 | Jan 1, 2023 | -$173.89 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.21 | – |
| Q2 FY2026 | Jun 30, 2026 | -$2.56 | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.29 | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.43 | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.46 | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.18 | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.10 | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.89 | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.94 | – |
| Q2 FY2024 | Jun 30, 2024 | -$51.06 | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.05 | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.04 | – |
| Q3 FY2023 | Oct 1, 2023 | -$28.71 | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.22 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?